Is time to joint replacement a valid outcome measure in clinical trials of drugs for osteoarthritis?
Each of the five sets of criteria for THA mentioned in this article should be regarded as preliminary. They require validation in future studies conducted in various cohorts of patients and in different countries. Moreover, a set of generally accepted criteria is badly needed. The number of proposed sets of criteria listed in this article indicates clearly that no consensus presently exists with respect to the optimal time for a patient who has hip OA to undergo THA.
Maillefert
Jean-Francis
JF
Department of Rheumatology, Dijon University Hospital, INSERM ERIT-M 0207, Department of Rheumatology, University of Burgundy, Hôpital Général, Dijon, France.
Dougados
Maxime
M
D019644:Arthroplasty, Replacement, Hip; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D006801:Humans; D007391:International Cooperation; D010003:Osteoarthritis / Q000188:drug therapy* / Q000601:surgery; D012016:Reference Values; D013997:Time Factors; D016896:Treatment Outcome